Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis

English version České info

Background:
Cryptococcal meningitis (CM) is the most common form of meningitis in Africa. World Health Organization guidelines recommend 14-d amphotericin-based induction therapy; however, this is impractical for many resource-limited settings due to cost and intensive monitoring needs. A cost-effectiveness analysis was performed to guide stakeholders with respect to optimal CM treatment within resource limitations.

Methods and Findings:
: We conducted a decision analysis to estimate the incremental cost-effectiveness ratio (ICER) of six CM induction regimens: fluconazole (800–1,200 mg/d) monotherapy, fluconazole + flucytosine (5FC), short-course amphotericin (7-d) + fluconazole, 14-d of amphotericin alone, amphotericin + fluconazole, and amphotericin + 5FC. We computed actual 2012 healthcare costs in Uganda for medications, supplies, and personnel, and average laboratory costs for three African countries. A systematic review of cryptococcal treatment trials in resource-limited areas summarized 10-wk survival outcomes. We modeled one-year survival based on South African, Ugandan, and Thai CM outcome data, and survival beyond one-year on Ugandan and Thai data. Quality-adjusted life years (QALYs) were determined and used to calculate the cost-effectiveness ratio and ICER. The cost of hospital care ranged from $154 for fluconazole monotherapy to $467 for 14 d of amphotericin + 5FC. Based on 18 studies investigating outcomes for HIV-infected individuals with CM in resource-limited settings, the estimated mean one-year survival was lowest for fluconazole monotherapy, at 40%. The cost-effectiveness ratio ranged from $20 to $44 per QALY. Overall, amphotericin-based regimens had higher costs but better survival. Short-course amphotericin (1 mg/kg/d for 7 d) with fluconazole (1,200 mg/d for14 d) had the best one-year survival (66%) and the most favorable cost-effectiveness ratio, at $20.24/QALY, with an ICER of $15.11 per additional QALY over fluconazole monotherapy. The main limitation of this study is the pooled nature of a systematic review, with a paucity of outcome data with direct comparisons between regimens.

Conclusions:
Short-course (7-d) amphotericin induction therapy coupled with high-dose (1,200 mg/d) fluconazole is “very cost effective” per World Health Organization criteria and may be a worthy investment for policy-makers seeking cost-effective clinical outcomes. More head-to-head clinical trials are needed on treatments for this neglected tropical disease.

: Please see later in the article for the Editors' Summary.

Vyšlo v časopise: Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Med 9(9): e32767. doi:10.1371/journal.pmed.1001316
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001316

Souhrn

Zdroje

1. ParkBJ, WannwmuehlerKA, MarstonBJ, GovenderN, PappasPG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525–530.

2. LiechtyCA, SolbergP, WereW, EkwaruJP, RansomRL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929–935.

3. World Health Organization (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization. Available: http://whqlibdoc.who.int/publications/2011/9789241502979_eng.pdf. Accessed 31 May 2012.

4. DromerF, Bernede-BauduinC, GuillemotD, LortholaryO (2008) Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 3: e2870 doi:10.1371/journal.pone.0002870.

5. van der HorstCM, SaagMS, CloudGA, HamillRJ, GraybillJR, et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337: 15–21.

6. Day JN, Chau TTH, Dung NT, Mai PP, Phu NH, et al. (2011) Combination antifungal therapy for HIV associated cryptococcal meningitis [abstract]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 September 2011; Chicago, Illinois, United States.

7. BrouwerAE, RajanuwongA, ChierakulW, GriffinGE, LarsenRA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764–1767.

8. PappasPG, ChetchotisakdP, LarsenRA, ManosuthiW, MorrisMI, et al. (2009) A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 48: 1775–1783.

9. BicanicT, MeintjesG, WoodR, HayesM, RebeK, et al. (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45: 76–80.

10. Bicanic T, Jarvis J, Loyse A, Jackson A, Muzoora C, et al. (2011) Determinants of acute outcome and long-term survival in HIV-associated cryptococcal meningitis: results from a combined cohort of 523 patients [abstract]. 18th Conference on Retroviruses and Opportunistic Infections; 27 Feb–2 Mar 2011; Boston, Massachusetts, United States.

11. NussbaumJC, JacksonA, NamarikaD, PhulusaJ, KenalaJ, et al. (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50: 338–344.

12. LongleyN, MuzooraC, TaseeraK, MwesigyeJ, RwebemberaJ, et al. (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 47: 1556–1561.

13. MuzooraCK, KabandaT, OrtuG, SsentamuJ, HearnP, et al. (2012) Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 64: 76–81.

14. BicanicT, MuzooraC, BrouwerAE, MeintjesG, LongleyN, et al. (2009) Independent association between rate of clearance of infection and clinical outcome of HIV associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 49: 702–709.

15. JacksonA, NussbaumJ, PhulusaJ, NamarikaD, ChikasemaM, et al. (2012) A phase II randomised controlled trial adding oral flucytosine to high dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis in Malawi. AIDS 26: 1363–1370.

16. Joint Medical Store (2011) Catalogue. Available: http://www.jms.co.ug/uploads/catalogue.pdf. Accessed 31 May 2012.

17. Bartlett JG, Auwaerter PG, Pham PA (2012) Johns Hopkins ABX guide: diagnosis and treatment of infectious disease, 3rd edition. Baltimore(Maryland): Jones and Bartlett Learning.

18. BicanicT, BrouwerAE, MeintjesG, RebeK, LimmathurotsakulD, et al. (2009) Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23: 701–706.

19. JacobST, MooreCC, BanuraP, PinkertonR, MeyaD, et al. (2009) Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLoS ONE 4: e7782 doi:10.1371/journal.pone.0007782.

20. BoulwareDR, MeyaDB, BergemannTL, WiesnerDL, RheinJ, et al. (2010) Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 7: e1000384 doi:10.1371/journal.pmed.1000384.

21. ManosuthiW, ChottanapundS, SungkanuparphS (2008) Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis. J Acquir Immune Defic Syndr 48: 508–509.

22. ChottanapundS, SinghasivanonP, KaewkungwalJ, ChamroonswasdiK, ManosuthiW (2007) Survival time of HIV-infected patients with cryptococcal meningitis. J Med Assoc Thai 90: 2104–2111.

23. KambuguA, MeyaDB, RheinJ, O'BrienM, JanoffEN, et al. (2008) Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 46: 1694–1701.

24. Butler E, Meya DB, Boulware DR (2011) Early treatment of Cryptococcal antigenemia improves long-term survival as compared to treatment of symptomatic cryptococcal meningitis in persons with HIV/AIDS [abstract]. 2011 Global Health Conference; 13–15 Nov 2011; Montreal, Canada.

25. MillsEJ, BakandaC, BirungiJ, ChanK, FordN, et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155: 209–216.

26. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.

27. Management Sciences for Health (2010) International drug price indicator guide: drug price search—search year: 2010. Available: http://erc.msh.org/dmpguide. Accessed 31 May 2012.

28. KisengePR, HawkinsAT, MaroVP, McHeleJP, SwaiNS, et al. (2007) Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis 7: 39.

29. WajangaBM, KalluvyaS, DownsJA, JohnsonWD, FitzgeraldDW, et al. (2011) Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J Int AIDS Soc 14: 48.

30. Mayanja-KizzaH, OishiK, MitaraiS, YamashitaH, NalongoK, et al. (1998) Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 26: 1362–1366.

31. TansuphaswadikulS, Maek-a-NantawatW, PhonratB, BoonpokbnL, MctmAG, et al. (2006) Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J Med Assoc Thai 89: 1677–1685.

32. BoulwareDR, BonhamSC, MeyaDB, WiesnerDL, ParkGS, et al. (2010) Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 202: 962–970.

33. Chang CC, Dorasamy AA, Elliott JH, Naranbhai V, Gosnell BI, et al. (2012) HIV-infected patients with cryptococcal meningitis who attain CSF sterility pre-cART commencement experience improved outcomes in the first 24 weeks [abstract]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 Mar 2012; Seattle, Washington, United States.

34. LoyseA, WilsonD, MeintjesG, JarvisJN, BicanicT, et al. (2012) Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 54: 121–128.

35. BicanicT, WoodR, MeintjesG, RebeK, BrouwerA, et al. (2008) High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 47: 123–130.

36. JarvisJN, MeintjesG, RebeK, WilliamsGN, BicanicT, et al. (2012) Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 26: 1105–1113.

37. World Health Organization (2011) World health statistics 2011. Available: http://www.who.int/gho/publications/world_health_statistics/EN_WHS2011_Full.pdf. Accessed 31 May 2012.

38. KaplanJE, BensonC, HolmesKH, BrooksJT, PauA, et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 1–207.

39. PerfectJR, DismukesWE, DromerF, GoldmanDL, GraybillJR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50: 291–322.

40. Bahr N, Rolfes MAR, Musubire A, Nabeta H, Lo M, et al. (2011) The impact of routine electrolyte supplementation during amphotericin induction therapy in resource-limited settings [abstract]. 8th International Conference on Cryptococcus and Cryptococcosis; 1–5 May 2011; Charleston, South Carolina, United States.

41. GirmeniaC, GentileG, MicozziA, MartinoP (2001) Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 33: 915–916.

42. MayerJ, DoubekM, VorlicekJ (1999) Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 7: 51–55.

43. MeyaDB, ManabeYC, CastelnuovoB, CookBA, ElbireerAM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448–455.

44. JarvisJN, LawnSD, VogtM, BanganiN, WoodR, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856–862.

45. RajasinghamR, MeyaDB, BoulwareDR (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: 85–91 doi:10.1097/QAI.1090b1013e31824c31837e.

46. World Health Organization (2011) Data from the Global Health Observatory: country health profile—Uganda. Available: http://www.who.int/gho/countries/uga.pdf. Accessed 31 May 2012.

47. JarvisJN, PercivalA, BaumanS, PelfreyJ, MeintjesG, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019–1023.

48. PappasPG (2005) Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 40: 480–482.

49. ShohamS, CoverC, DoneganN, FulneckyE, KumarP (2005) Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 40: 477–479.

50. ManosuthiW, SungkanuparphS, ChottanapundS, TansuphaswadikulS, ChimsuntornS, et al. (2008) Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS 19: 268–271.

51. JarvisJN, LawnSD, WoodR, HarrisonTS (2010) Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis 51: 1463–1465.

52. World Health Organization (2011) WHO model list of essential medicines, 17th edition. Available: http://www.who.int/medicines/publications/essentialmedicines. Accessed 31 May 2012.